Class IV antiarrhythmic drugs, such as verapamil and diltiazem, block calcium channels. They primarily affect the heart, slowing the conduction in calcium-dependent tissues like the SA and AV nodes. These drugs manage reentrant supraventricular tachycardia (SVT) and reduce ventricular rate in atrial flutter/fibrillation.

Verapamil, a calcium channel blocker, inhibits calcium movement across myocardial cell membranes and vascular smooth muscle. This results in the dilation of coronary and peripheral arteries, reducing the force of cardiac contraction. Verapamil also slows conduction in the SA and AV nodes, decreasing heart rate. Diltiazem is similar to verapamil but has more impact on smooth muscle and causes less bradycardia. Both drugs can control SVT and manage the ventricular rate in atrial flutter/fibrillation. Adverse effects may include bradycardia, hypotension, and peripheral edema. It is important to note that calcium channel blockers have different effects on different tissues. Dihydropyridines like nifedipine mainly block calcium channels in vascular smooth muscle, leading to an increased heart rate due to sympathetic activation. Verapamil, diltiazem, and bepridil block calcium channels in cardiac cells, slowing the heart rate and prolonging the PR interval. Caution should be exercised using verapamil and diltiazem for ventricular tachycardia, as the risk of adverse effects is higher. Oral administration of these drugs generally results in milder side effects than bolus administration. Verapamil is prescribed as a racemate, with the L-enantiomer being more potent but subjected to first-pass hepatic metabolism when taken orally. Verapamil and diltiazem can increase serum digoxin concentration, which may excessively slow the ventricular response in patients with atrial fibrillation. Close monitoring of patients' heart conditions and drug interactions is necessary.

Although class IV antiarrhythmic drugs are used to manage SVT and atrial flutter/fibrillation, they show adverse effects, including bradycardia, hypotension, and peripheral edema. Caution should be exercised when using these drugs; careful monitoring is required for drug interactions.

Tags
Antiarrhythmic DrugsClass IV AgentsCalcium Channel BlockersVerapamilDiltiazemSupraventricular TachycardiaAtrial FlutterCardiac ConductionBradycardiaHypotensionPeripheral EdemaDihydropyridinesMyocardial Cell MembranesDrug InteractionsHeart Rate Management

From Chapter 10:

article

Now Playing

10.6 : Antiarrhythmic Drugs: Class IV Agents as Calcium Channel Blockers

Cardiovascular Drugs: Antiarrhythmic and Heart Failure Drugs

601 Views

article

10.1 : Electrophysiology of Normal Cardiac Rhythm

Cardiovascular Drugs: Antiarrhythmic and Heart Failure Drugs

911 Views

article

10.2 : Mechanism of Cardiac Arrhythmias

Cardiovascular Drugs: Antiarrhythmic and Heart Failure Drugs

780 Views

article

10.3 : Antiarrhythmic Drugs: Class I Agents as Sodium Channel Blockers

Cardiovascular Drugs: Antiarrhythmic and Heart Failure Drugs

886 Views

article

10.4 : Antiarrhythmic Drugs: Class II Agents as β-Adrenergic Blockers

Cardiovascular Drugs: Antiarrhythmic and Heart Failure Drugs

597 Views

article

10.5 : Antiarrhythmic Drugs: Class III Agents as Potassium Channel Blockers

Cardiovascular Drugs: Antiarrhythmic and Heart Failure Drugs

738 Views

article

10.7 : Pathophysiology of Cardiac Performance

Cardiovascular Drugs: Antiarrhythmic and Heart Failure Drugs

397 Views

article

10.8 : Pathophysiology of Heart Failure

Cardiovascular Drugs: Antiarrhythmic and Heart Failure Drugs

1.2K Views

article

10.9 : Heart Failure Drugs: Inotropic Agents

Cardiovascular Drugs: Antiarrhythmic and Heart Failure Drugs

312 Views

article

10.10 : Heart Failure Drugs: Diuretics

Cardiovascular Drugs: Antiarrhythmic and Heart Failure Drugs

216 Views

article

10.11 : Heart Failure Drugs: Inhibitors of Renin-Angiotensin System

Cardiovascular Drugs: Antiarrhythmic and Heart Failure Drugs

233 Views

article

10.12 : Heart Failure Drugs: β-Blockers

Cardiovascular Drugs: Antiarrhythmic and Heart Failure Drugs

174 Views

JoVE Logo

Privacy

Terms of Use

Policies

Research

Education

ABOUT JoVE

Copyright © 2025 MyJoVE Corporation. All rights reserved